Former FDA Commissioner Scott Gottlieb in 2017 (J. Scott Applewhite/AP Images, File)

December 2, 2024 01:15 PM EST

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Drew Armstrong

Executive Editor

Former FDA Commissioner Scott Gottlieb opposed President-elect Donald Trump’s choice to lead the Department of Health and Human Services, saying Robert F. Kennedy Jr.’s policies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Novocure says electric field therapy extends life for pancreatic cancer patients by two months

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

Drew Armstrong

Executive Editor

Sign up to read this article for free.

more like this

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Ole­ma, No­var­tis ink an­oth­er agree­ment, this time for a late-stage breast can­cer tri­al

Sen­ti Bio’s Phase 1 CAR-NK da­ta; Allink rais­es $42M

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Novocure says electric field therapy extends life for pancreatic cancer patients by two months

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M